Posted by Michael Wonder on 27 Sep 2023
FDA accepts submission to add PH-ILD to Yutrepia label
26 September 2023 - Sets PDUFA goal date of 24 January 2024.
Liquidia Corporation announced today that the US FDA accepted for review the Company’s amendment to the tentatively approved new drug application for Yutrepia (treprostinil) inhalation powder in which the Company is seeking to add the treatment of pulmonary hypertension associated with interstitial lung disease to the label.
